Abstract
Erdafitinib (Balversa, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
